Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: Inhibition by NSAIDs

British Journal of Clinical Pharmacology

Volumn 68, Issue 3, 2009, Pages 402-412

  Knights, Kathleen M ^a   Winner, Leanne K ^a   Elliot, David J ^a   Bowalgaha, Kushari ^a   Miners, John O ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Aldosterone; Glucuronidation; Non steroidal anti inflammatory drugs; Renal drug metabolism

Indexed keywords

ALCLOFENAC; ALDOSTERONE; ALDOSTERONE 18BETA GLUCURONIDE; CICLOPROFEN; DICLOFENAC; DIFLUNISAL; FENOPROFEN; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B10; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMIC ACID; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIRPROFEN; TIAPROFENIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; KIDNEY MICROSOME; MALE; PRIORITY JOURNAL; WATER RETENTION;

ADULT; AGED; ALDOSTERONE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY; KINETICS; LIVER; MALE; MICROSOMES; MIDDLE AGED;

EID: 69949147669     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03469.x     Document Type: Article

References (43)

1. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993 32 : 435 465.
2. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO. Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 2005 60 : 423 433.
3. Brunelle FM, Verbeeck RK. Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. Xenobiotica 1996 26 : 123 131.
4. King C, Tang W, Nqui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001 61 : 49 53.
5. Miners JO, Knights KM, Houston JB, Mackenzie PI. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans; Pitfalls and promises. Biochem Pharmacol 2006 71 : 1531 1539.
6. McGurk KA, Brierley CH, Burchell B. Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 1998 55 : 1005 1012.
7. Soars MG, Riley RJ, Findlay KA, Coffey MJ, Burchell B. Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos 2001 29 : 121 126.
8. Soars MG, Burchell B, Riley RJ. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 2002 301 : 382 390.
9. Gaganis P, Miners JO, Knights KM. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Biochem Pharmacol 2007 73 : 1683 1691.
10. Gaganis P, Miners JO, Brennan JS, Thomas A, Knights KM. Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. J Pharmacol Exp Ther 2007 323 : 1 9.
11. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. Predicting human drug glucuronidation parameters: application of in vitro and in silico modelling approaches. Annu Rev Pharmacol Toxicol 2004 44 : 1 25.
12. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005 15 : 677 685.
13. Sorich MJ, McKinnon RA, Miners JO, Smith PA. The importance of local chemical structure for chemical metabolism by human uridine 5′-diphosphate glucuronosyltransferase. J Chem Inf Model 2006 46 : 2692 2697.
14. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Phamacol Exp Ther 1993 264 : 475 479.
15. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, King C. Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys 2004 424 : 219 225.
16. Bledsoe T, Liddle GW, Riondel A, Island DP, Bloomfield D, Sinclair-Smith B. Comparative fates of intravenously and orally administered aldosterone: evidence for extrahepatic formation of acid-hydrolyzable conjugate in man. J Clin Invest 1966 45 : 264 269.
17. Girard C, Barbier O, Veilleux G, El-Alfy M, Belanger A. Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology 2003 144 : 2659 2668.
18. Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2 selective inhibitors. Am J Nephrol 2001 21 : 1 15.
19. Kokko JP. Effect of prostaglandins on renal epithelial electrolyte transport. Kidney Int 1981 19 : 791 796.
20. + absorption by activating the EP1 receptor. J Clin Invest 1998 102 : 194 201.
21. de Broe ME, Porter GA, Bennett WM, Verpooten GA. Clinical Nephrotoxins: Renal Injury From Drugs and Chemicals, 2nd edn. London : Kluwer Academic Publishers, 2003 280 306.
22. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991 31 : 588 598.
23. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, Knights KM. Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 2004 67 : 191 199.
24. Boase S, Miners JO. In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 2002 54 : 493 503.
25. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 2003 31 : 1086 1089.
26. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 2004 32 : 413 423.
27. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 2006 34 : 1055 1062.
28. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) 'probes' for human UDP-glucuronosyltransferases. Drug Metab Dispos 2006 34 : 449 456.
29. Sykes M, Sorich M, Miners JO. Molecular approaches for the prediction of the non-specific binding of drugs to hepatic microsomes. J Chem Inf Model 2006 46 : 2661 2673.
30. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams A, Miners JO. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 2006 61 : 427 439.
31. Miners JO, Lillywhite KJ, Matthews AP, Jones ME, Birkett DJ. Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. Biochem Pharmacol 1988 37 : 665 671.
32. Kerdpin O, Knights KM, Elliot DJ, Miners JO. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Biochem Pharmacol 2008 76 : 249 257.
33. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J. Pharmacol Ther 2007 321 : 137 147.
34. Rowland A, Knights KM, Mackenzie PI, Miners JO. The 'albumin effect' and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 2008 36 : 870 877.
35. Rowland A, Knights KM, Mackenzie PI, Miners JO. The 'albumin effect' and drug glucuronidation: bovine serum albumin and fatty acid free albumin enhance the glucuronidation of UGT1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 2008 36 : 1056 1062.
36. Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 2001 52 : 605 609.
37. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000 40 : 581 616.
38. Neuvonen PJ, Kivisto KT. Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. Eur J Clin Pharmacol 1988 35 : 495 501.
39. Hinz B, Chevts J, Renner B, Wuttke H, Rau T, Schmidt A, Szelenyi I, Brune K, Werner U. Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol 2005 59 : 80 4.
40. Charles BG, Mogg GA. Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations. Biopharm Drug Dispos 1994 15 : 121 128.
41. Gambro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003 253 : 643 652.
42. Lopez-Hernandez F, Lopez-Novoa JM. The lord of the ring: mandatory role of the kidney in drug therapy of hypertension. Pharmacol Ther 2006 111 : 53 80.
43. Morgan T, Anderson A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens 2003 5 : 53 7.